Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.
CLLIPI
molecular testing
outcomes
real world evidence
treatments
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
13
05
2023
revised:
23
06
2023
accepted:
28
06
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
FISH cytogenetics, TP53 sequencing, and IGHV mutational status are increasingly used as prognostic and predictive markers in chronic lymphocytic leukemia (CLL), particularly as components of the CLL International Prognostic Index (CLL-IPI) and in directing therapy with novel agents. However, testing outside of clinical trials is not routinely available in Canada. As a centralized CLL clinic at CancerCare Manitoba, we are the first Canadian province to evaluate clinical outcomes and survivorship over a long period of time, incorporating the impact of molecular testing and the CLL-IPI score. We performed a retrospective analysis on 1315 patients diagnosed between 1960 and 2018, followed over a 12-year period, where 411 patients had molecular testing and 233 patients had a known CLL-IPI score at the time of treatment. Overall, 40.3% (
Identifiants
pubmed: 37504332
pii: curroncol30070472
doi: 10.3390/curroncol30070472
pmc: PMC10378068
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6411-6431Références
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii
pubmed: 15325699
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Leuk Lymphoma. 2019 Dec;60(13):3204-3213
pubmed: 31237469
Pharmacoeconomics. 2020 Sep;38(9):941-951
pubmed: 32383129
Hematol Oncol. 2017 Dec;35(4):664-670
pubmed: 27678008
JCO Glob Oncol. 2020 Jun;6:866-872
pubmed: 32579486
Lancet Oncol. 2016 Jun;17(6):779-790
pubmed: 27185642
Curr Oncol. 2018 Oct;25(5):e461-e474
pubmed: 30464698
Lancet Oncol. 2020 Sep;21(9):1188-1200
pubmed: 32888452
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713
J Manag Care Spec Pharm. 2020 Oct;26(10):1266-1275
pubmed: 32880204
Am J Hematol. 2017 Dec;92(12):1393-1397
pubmed: 28589701
Leuk Lymphoma. 2008 Jan;49(1):49-56
pubmed: 18203011
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Lancet. 2020 Apr 18;395(10232):1278-1291
pubmed: 32305093
Blood. 2014 May 22;123(21):3247-54
pubmed: 24652989
Hematol Oncol Clin North Am. 2021 Aug;35(4):827-845
pubmed: 34174988
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):763-775.e2
pubmed: 31678080
Discov Med. 2011 Feb;11(57):115-23
pubmed: 21356166
N Engl J Med. 2015 Dec 17;373(25):2425-37
pubmed: 26639149
Cancer Med. 2016 Jun;5(6):971-9
pubmed: 26889755
Leuk Lymphoma. 2018 Oct;59(10):2327-2335
pubmed: 29415595
N Engl J Med. 1990 Sep 13;323(11):720-4
pubmed: 2201915
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Leukemia. 2020 Mar;34(3):787-798
pubmed: 31628428
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Am J Hematol. 2016 Mar;91(3):330-40
pubmed: 26690614
Med Oncol. 2019 Aug 2;36(9):79
pubmed: 31375939
Am J Hematol. 2016 Nov;91(11):1090-1095
pubmed: 27465919
Cancer Genet Cytogenet. 2004 Aug;153(1):69-72
pubmed: 15325098
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Lancet Oncol. 2016 Jun;17(6):768-778
pubmed: 27178240
Br J Haematol. 2017 Aug;178(3):394-402
pubmed: 28580636
J Clin Oncol. 2007 Mar 1;25(7):799-804
pubmed: 17283363
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Blood. 2021 Dec 16;138(24):2589-2592
pubmed: 34521099
Best Pract Res Clin Haematol. 2016 Mar;29(1):90-99
pubmed: 27742075
Lancet Oncol. 2018 Jan;19(1):65-75
pubmed: 29246803
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Blood. 1995 Mar 15;85(6):1580-9
pubmed: 7888675
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
N Engl J Med. 2014 Jul 17;371(3):213-23
pubmed: 24881631
Blood Cancer J. 2018 Oct 3;8(10):93
pubmed: 30283014
Curr Hematol Malig Rep. 2017 Feb;12(1):11-19
pubmed: 28116634
Br J Cancer. 2013 Sep 3;109(5):1287-90
pubmed: 23860531
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Exp Oncol. 2005 Dec;27(4):325-9
pubmed: 16404355
J Clin Oncol. 2010 Oct 10;28(29):4473-9
pubmed: 20697090
Leuk Res. 2009 Nov;33(11):1463-8
pubmed: 19581000
Leuk Res. 2023 Feb;125:107016
pubmed: 36634577
N Engl J Med. 2023 May 11;388(19):1739-1754
pubmed: 37163621
Br J Haematol. 2019 Oct;187(1):e8-e11
pubmed: 31364153
Blood. 2011 May 12;117(19):5019-32
pubmed: 21300984
Aust N Z J Med. 1990 Feb;20(1):44-50
pubmed: 2322201
Blood Cancer J. 2021 Aug 5;11(8):140
pubmed: 34354039
Blood. 2016 Oct 20;128(16):2093-2095
pubmed: 27549308
Neoplasma. 2009;56(5):455-8
pubmed: 19580349
Curr Oncol. 2023 Apr 24;30(5):4483-4498
pubmed: 37232797
Blood. 2015 Apr 16;125(16):2497-506
pubmed: 25700432
Leukemia. 2015 Jul;29(7):1602-4
pubmed: 25634683
Blood. 2022 Jul 14;140(2):112-120
pubmed: 35427411
Annu Rev Pathol. 2014;9:103-18
pubmed: 23987584